Literature DB >> 16389235

Trastuzumab (Herceptin) and HER2-positive breast cancer.

Sally Murray.   

Abstract

Entities:  

Year:  2006        PMID： 16389235      PMCID： PMC1319343          DOI： 10.1503/cmaj.051452

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

2.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Authors:  Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

3.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245
  3 in total
  3 in total

1.  Media influence on Herceptin subsidization in Australia: application of the rule of rescue?

Authors:  Ross Mackenzie; Simon Chapman; Glenn Salkeld; Simon Holding
Journal:  J R Soc Med       Date:  2008-06       Impact factor: 5.344

2.  Integrated diagnostic network construction reveals a 4-gene panel and 5 cancer hallmarks driving breast cancer heterogeneity.

Authors:  Xiaofeng Dai; Tongyan Hua; Tingting Hong
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

3.  FA2H Exhibits Tumor Suppressive Roles on Breast Cancers via Cancer Stemness Control.

Authors:  Xiaofeng Dai; Shuo Zhang; Hongye Cheng; Dongyan Cai; Xiao Chen; Zhaohui Huang
Journal:  Front Oncol       Date:  2019-10-24       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.